Prediction of Genitourinary Tract Morbidity After Brachytherapy for Prostate Adenocarcinoma

Wehle, Michael J.; Lisson, Scott W.; Buskirk, Steven J.; Broderick, Gregory A.; Young, Paul R.; Igel, Todd C.
March 2004
Mayo Clinic Proceedings;Mar2004, Vol. 79 Issue 3, p314
Academic Journal
• Objective: To investigate whether preoperative genitourinary variables in patients undergoing brachytherapy for localized prostate adenocarcinoma could predict post- operative genitourinary tract morbidity. • Patients and Methods: We retrospectively reviewed medical records of 105 men who received either iodine 125 or palladium 103 radioactive seed implants with or without external beam radiotherapy or hormone blockade from January 1, 1998, through December 31,2000, at the Mayo Clinic in Jacksonville, Fla. Patients with one or more of the following were classified as having a high risk of postoperative genitourinary tract morbidity: American Urological Association symptom scores greater than 15, maximum urinary flow rate less than 10 mL/s, postvoid residual urinary volume greater than 100 mL, or prostate volume greater than 40 cm3. Of the 105 men, 59 (56%) were classified as high risk and 46(44%) as low risk. Mean follow-up after brachytherapy was 23.6 months. Modified Radiation Therapy Oncology Group scores were used to assess postoperative genitourinary tract morbidity. The term significant genitourinary tract morbidity was applied to patients with a Radiation Therapy Oncology Group grade of 3 or 4 after at least 6 months of follow-up. • Results: Significant morbidity occurred in 37% of high-risk vs 15% of low-risk patients (P=.006). In high-risk patients, transurethral resection or incision of the prostate was required in 5 patients, urethral dilation in 4, direct-vision internal urethrotomy in 1, and placement of a suprapubic catheter in 1. In low-risk patients, transurethral incision of the prostate was required in only 1 patient. Urinary flow rate was a significant individual predictor of postoperative morbidity (P=.03).


Related Articles

  • Normal tissue complication probability: Does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma. Basu, K. S. Jothy; Bahl, Amit; Subramani, V.; Sharma, D. N.; Rath, G. K.; Julka, P. K. // Journal of Cancer Research & Therapeutics;Apr-Jun2009, Vol. 5 Issue 2, p78 

    Aim: The main objective of this study was to analyze the radiobiological effect of different treatment strategies on high-risk prostate adenocarcinoma. Materials and Methods: Ten cases of high-risk prostate adenocarcinoma were selected for this dosimetric study. Four different treatment...

  • 155-6. THE DILEMMA OVER PSA SCREENING.  // Cortlandt Forum;01/25/2001, Vol. 14 Issue 1, p80 

    Discusses an appropriate screening strategy for prostate-specific antigen (PSA). Controversy surrounding serum PSA testing as a screening tool for prostate cancer; Need for a screening test to identify disease sufficiently early in its course; Clinicians' adoption of a program of annual testing...

  • Hypofractionated IMRT Is a Viable Option.  // Renal & Urology News;Jan2012, Vol. 11 Issue 1, p11 

    The article reports on the findings of a study which revealed the viability of hypofractionated intensity modulated radiotherapy (IMRT) as a practical approach to effectively preventing recurrence of intermediate or high-risk prostate cancer (PCa) at five years after treatment.

  • Does Testosterone Therapy Increase the Risk of Prostate Cancer? Adrian Dobs // Endocrine Practice;Oct2008, Vol. 14 Issue 7, p904 

    Objective: To review factors affecting use of testosterone therapy for hypogonadism including the persistent controversial link between testosterone therapy and prostate cancer.Methods: We reviewed studies investigating the relationship between testosterone therapy and prostate cancer...

  • Study recommends 4-year screening interval for PCa. Guttman, Cheryl // Urology Times;Nov2003, Vol. 31 Issue 11, p1 

    Reports on the findings of a medical study recommending at least a four-year interval in prostate cancer screening. Research on the sensitivity of initial screening and cancer rate interval during the initial four-year follow-up period after randomization; Consideration for prognostic factors;...

  • Brachytherapy for Prostate Cancer: A Systematic Review. Koukourakis, Georgios; Kelekis, Nikolaos; Armonis, Vassilios; Kouloulias, Vassilios // Advances in Urology;2009, Special section p1 

    Low-dose rate brachytherapy has become a mainstream treatment option for men diagnosed with prostate cancer because of excellent long-term treatment outcomes in low-, intermediate-, and high-risk patients. To a great extend due to patient lead advocacy forminimally invasive treatment options,...

  • What's New At NEIU? Detweiler, Donna // Business People;Sep2015, Vol. 28 Issue 9, p61 

    A review is offered for the Northeast Indiana Urology, a prostate cancer treatment center located in Indiana.

  • Fitting competing risks with an assumed copula. Escarela, Gabriel; Carri�re, Jacques F. // Statistical Methods in Medical Research;Aug2003, Vol. 12 Issue 4, p333 

    We propose a fully parametric model for the analysis of competing risks data where the types of failure may not be independent. We show how the dependence between the cause-specific survival times can be modelled with a copula function. Features include: identifiability of the problem;...

  • Prostate cancer screening: A refined strategy. Pinkowish, Mary Desmond // Patient Care;11/30/2000, Vol. 34 Issue 22, p9 

    Compares the efficiency of prostate-specific antigen (PSA) screening strategies for prostate cancer detection; Practice of measuring PSA levels annually beginning at age 50 years; Baseline PSA screening at age 40 and again at age 45 years.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics